SiNtx Technologies Inc (SINT)

[boston745]

As best as I can figure out, low marketcap coupled with restricted stock ownership levels encourages the shorting of companies. Companies are restricted to 10% ownership in Sintx case. Once you RS from 36m to 3m as was done in 2017, 10% ownership is only 300k shares. With the companies marketcap being so low hfunds receive thousands/millions of preferred shares/warrants instead of hundreds of thousands of common stock for a company to raise 15m. As such hfunds must naked short these stocks so they can convert as naked shorting allows for them to bypass restricted ownership levels. This causes the nosedive.

Had amedica been valued properly this course of action would not occur, it's a direct result of its non-exsistent marketcap. If the SEC ever looks into things here I hope they do look into how, despite the progresses made in IP development and improvements to balance sheet, Amedicas marketcap continued to drop. Obviously some will say it's the drop in revenue, but thats more than offset by IPR&D especially if you consider the real value of sales was generating clinical data.

The other day I compared Sintx upcoming next generation of spinal implants to Spinal Dynamics with its innovative Cervical Disc. Both products represent a leap in technology for which Medtronic paid 270m for the cervical disc technology that lacked much in the way of clinical data. That means that Sintx next generation of spinal implants should be worth at least 270m given the market is 3-4x bigger than it was in 2003 & that Sintx implants are backed by years of successful clinical data (up to 30 years in one small study).

I would argue the clinical data, as has been pointed out by others, is the 2nd most valuable piece assembled outside of actual IP development. Supporting all this are the various scientific studies explaining how the implants perform in a biological enviornment so surgeons can understand how this material achieves what it does.

All this points to Sintx true value far exceeding its current value which is what Ive been arguing for the last 3 years. How Sintx marketcap was allowed to be raped in such a way by the market I would like to further understand one day. This is an example of how the SEC continues to fail retail investors and the innovative companies they invest in.